Stocks and Investing Stocks and Investing
Wed, February 28, 2024

Gena Wang Maintained (BEAM) at Hold with Increased Target to $42 on, Feb 28th, 2024


Published on 2024-10-28 09:16:30 - WOPRAI, Gena Wang
  Print publication without navigation


Gena Wang of Barclays, Maintained "Beam Therapeutics Inc." (BEAM) at Hold with Increased Target from $26 to $42 on, Feb 28th, 2024.

Gena has made no other calls on BEAM in the last 4 months.



There are 3 other peers that have a rating on BEAM. Out of the 3 peers that are also analyzing BEAM, 2 agree with Gena's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Greg Harrison of "B of A Securities" Downgraded from Strong Buy to Hold and Held Target at $35 on, Friday, December 15th, 2023
  • Michael Yee of "Jefferies" Downgraded from Strong Buy to Hold and Decreased Target to $30 on, Friday, December 8th, 2023


This is the rating of the analyst that currently disagrees with Gena


  • Eric Joseph of "JP Morgan" Upgraded from Hold to Buy and Increased Target to $40 on, Monday, January 29th, 2024
Contributing Sources